TriangleIpilimumab and Nivolumab (NCT07075120)
Ipilimumab and Nivolumab trial for Hepatocellular Carcinoma (HCC) (NCT07075120). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for locally advanced hepatocellular carcinoma, a liver cancer, in adults.
The idea: combine two immunotherapy drugs, ipilimumab and nivolumab, with targeted radiation before surgery. Patients first receive the drugs for nine weeks. Scans then show whether the tumor can be removed. If not, immunotherapy continues with radiation in three to five treatments, and surgery follows once removal is possible.
This pilot phase 1 study plans 15 patients and measures feasibility. At the University of Hawaii in Honolulu, Jared Acoba leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.